InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Completed Production of a Test Batch of its SmoothX™ Barium Sulfate CT Contrast Media Oral Suspension for the Canadian CT Imaging Market
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has completed production of a test batch of its SmoothX barium sulfate CT contrast media oral suspension for the CT imaging market in Canada.
- VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has completed production of a test batch of its SmoothX barium sulfate CT contrast media oral suspension for the CT imaging market in Canada.
- It also marks a key point in our journey to create a fully integrated Canadian supply chain for barium contrast media.
- It also supports Canadas national strategy of de-coupling from China for the supply of critical minerals and critical pharmaceutical production.
- InvestmentPitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information.